Epidemiological Methods: About Time by Kraemer, Helena Chmura
Int. J. Environ. Res. Public Health 2010, 7, 29-45; doi:10.3390/ijerph7010029 
 
International Journal of 
Environmental Research and 
Public Health 
ISSN 1660-4601 
www.mdpi.com/journal/ijerph 
Article 
Epidemiological Methods: About Time  
Helena Chmura Kraemer
 1,2 
1  Department of Psychiatry and Behavioral Sciences, Stanford University, 1116 Forest Avenue, Palo 
Alto, CA 94301, USA 
2  Department of Psychiatry, University of Pittsburgh, 3811 O'Hara Street, Pittsburgh, PA 15213, 
USA; E-Mail: hckhome@pacbell.net; Tel.: +1-650-328-7564 
Received: 29 October 2009 / Accepted: 24 December 2009 / Published: 31 December 2009 
 
Abstract:  Epidemiological  studies  often  produce  false  positive  results  due  to  use  of 
statistical approaches that either ignore or distort time. The three time-related issues of focus 
in this discussion are: (1) cross-sectional vs. cohort studies, (2) statistical significance vs. 
public health significance, and (3), how risk factors ―work together‖ to impact public health 
significance. The issue of time should be central to all thinking in epidemiology research, 
affecting  sampling,  measurement,  design,  analysis  and,  perhaps  most  important,  the 
interpretation of results that might influence clinical and public-health decision-making and 
subsequent clinical research.  
Keywords:  risk  factors;  statistical  and  clinical  significance;  effect  sizes;  moderators; 
mediators  
 
 
1. Introduction  
 
Epidemiology has been defined as the ―study of the distribution and determinants of health-related 
states  or  events  in  specified  populations,  and  the  application  of  this  study  to  control  of  health 
problems‖ [1] (Page 55). ―Distribution‖ refers to incidence or prevalence of disorders in specified time 
periods. ―Determinants‖ refers to risk factors (some causal, some not) for disorders, factors that can be 
shown to identify individuals who at a later time are more likely to have the disorder. ―Application‖ 
refers in part to prevention of disorders in the subsequent period of time by manipulating causal risk 
factors  among  those  as  yet  without  the  disorder.  All  such  tasks  are  crucially  dependent  on 
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considerations of time. While other types of questions also fall within the bailiwick of epidemiology 
research, the unique contribution of epidemiology research is guidance based on observational studies 
provided  for  the  prediction  and  prevention  of  disorders,  both  crucially  time-related.  Yet  such 
epidemiological studies have often produced false positive results [2-5], even studies that seem well 
and carefully designed, executed, and analyzed. At least part of that problem relates to the statistical 
methods used in epidemiology, many of which ignore or distort time.  
In what follows, we address three interlocking areas of such concern in observational studies in 
human populations: (1) cross-sectional vs. prospective longitudinal (cohort) studies and their design; 
(2) statistical significance vs. public health significance and (3), how risk factors ―work together‖ to 
impact public health significance. None of these issues is completely novel, but the problems they 
generate continue to affect epidemiological studies, and it is worth considering why this is so.  
 
2. Cross-Sectional and Prospective Longitudinal (Cohort) Studies  
 
To show that some factor is a ―risk factor‖ for a disorder, it must be shown both that: (a) the factor 
precedes onset of the disorder, and (b) it is correlated with the disorder [6]. A factor that is correlated 
with presence/absence of a disorder in a cross-sectional study may be a symptom of, or a result of, the 
disorder,  not  a  risk  factor  for  it.  Presence  or  absence  of  the  disorder  may  be  indicated  either  by 
prevalence or incidence within a specified time period.  
For a  disorder that is  chronic and  persistent  after onset,  prevalence at  a certain age equals the 
incidence between birth and that age for those that survive to that age. Otherwise, for a disorder from 
which there may be remissions or recoveries, or one associated with removals from the population, 
cross  sectional  correlations  may  relate  as  much  to  the  association  of  factors  related  to  treatment 
availability and response, or inconsistency of expression over time, as to risk of incurring the disorder. 
Consequently cross-sectional studies investigating correlates of prevalence of episodic disorders are of 
limited use in identifying determinants of those disorders or ways of preventing them, although they 
may be vital in setting the stage for prospective studies to accomplish those purposes.  
One exception relates to the detection of ―fixed markers‖ [6], i.e., risk factors that are fixed over the 
course  of  the  lifetime  of  individuals,  e.g.,  gender,  ethnicity/race,  year  of  birth,  and,  in  general, 
genotype. Since fixed markers exist at birth and remain unchanged over the lifetime of the individual, 
these are temporally precedent to onset of all disorders during the individual‘s lifetime. Thus to show 
correlation between a fixed marker and presence/absence of a disorder in a cross-sectional study is to 
establish that the variable is a risk factor for that disorder, although the association may be weaker than 
that between the fixed marker and an incidence. Fixed markers are crucial to identification of ―high 
risk‖ subpopulations, thus both to designing research studies and to targeting interventions, but since 
fixed markers cannot be changed, they are of little value to designing interventions to prevent onset  
of disorders.  
The ideal, but admittedly unrealistic, approach to demonstrate risk factor status would be to sample 
the relevant population disorder free at a designated time zero (t = 0), to evaluate potential risk factors 
at that time, to follow each sampled individual over his/her subsequent lifetime, in order to evaluate 
and compare survival curves to the onset of the disorder [7] over that time period to see for whom and Int. J. Environ. Res. Public Health 2010, 7                 
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when onsets occur. With a binary risk factor (RF = 1 identifying ―high risk‖ individuals and RF = 0 
―low-risk‖), one might see a situation such as that in Figure 1, which shows hypothetical survival 
curves to onset of a disorder for the ―high risk‖ subpopulation (S1(t) in those with RF = 1) and the ―low 
risk‖ subpopulation (S0(t) in those with RF = 0) for all values of t.  
Figure  1.  Comparison  of two hypothetical survival curves for the subpopulations with  
RF = 1 and RF = 0 (non-proportional hazards).  
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Then one could not only compare the overall survival curves, but could compare the incidence 
between  time  0  and  any  fixed  time  T  [1-S1(T) vs.  1-S0(T)].  In this  hypothetical  example, (1) the 
survival curves cross at t = T*, an unusual, although not an unknown, situation, and (2) onset is not 
inevitable for every individual, which is a quite common situation. In this example, 50% in one group 
have onset during their lifetimes compared to 30% in the other group, but the latter are likely to have 
their onset early if at all, which results in the crossing of survival curves, here at T* ≈ 18. 
Here if incidences prior to T* are compared, RF would appropriately be described as a risk factor 
for  the  disorder;  after  T*,  as  a  protective  factor  against  the  disorder.  Exactly  at  T*  the  factor  is 
unrelated  to  the  incidence  of  the  disorder.  This  illustrates  the  general  principle  that  conclusions 
concerning the relationship of any risk factor for a disorder may depend strongly on the exact time span 
to which incidence refers.  
Because it is more convenient to have short follow-up times, epidemiologists often assume that 
whatever the relative positions of the two survival curves near zero are the relative positions for all 
follow-up times. This is one of those extrapolations that often mislead both subsequent research efforts 
and clinical decision making. In general, the inferences from a cohort study apply to those in the 
disorder-free subpopulation represented in the sample at time 0, and followed for as long as the study Int. J. Environ. Res. Public Health 2010, 7                 
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chooses to follow the individuals, whether that be 1, 2, 5 or 10 years, but not necessarily to another 
population, and for any longer. Explicit presentation of the estimated survival curves up to the end of 
follow-up, as a general practice, would not only inform medical consumers as to exactly the findings of 
the study up to the duration of follow-up, but also remind them of the time limitations on inferences.  
Standard survival methods [8] used to estimate survival curves deal well with ―censored‖ data. Thus 
if the intended follow-up time is 10 years, but some individuals are lost to follow-up, still onset-free, 
after 1,2,3,… years, the survival curves can still be estimated up to 10 years using these methods, 
provided loss to follow-up is not associated with the same mechanism that produces onset. Thus, for 
example, in comparing those who did or did not use hormone replacement therapy (HRT) on time to 
onset of coronary disease [9], one cannot treat those with onset of cancer, cognitive disability, or the 
occurrence  of  a  stroke  as  a  ―censored‖  data  point,  for  HRT  may  be  a  risk  factor  for  all  these  
outcomes [10]. If such competing outcomes were mutually exclusive, observing the occurrence of any 
one before the others would indicate non-occurrence of the others at any later time, in which case that 
would not be a ―censored‖ data point, but a signal of the longest possible survival time. However, such 
outcomes are not usually mutually exclusive. One may, for example, have both onset of coronary 
disease and subsequently onset of cognitive disability or vice versa. This is an unavoidable problem 
when risk factors are, as they often are, non-specific to one disorder, and epidemiologists seek to 
estimate the effect on each specific disorder separately.  
Moreover, how the zero-point of time (t = 0) is defined makes a major difference in conclusions. 
For example, in the hypothetical situation in Figure 1, let us say that t = 0 refers to time of birth for the 
individuals in the population. If instead, individuals were sampled at the age of 10 or 20 or 50 (t = 0 in 
each case defined as the age at which individuals are sampled and their risk factors assessed), the 
populations sampled would differ, for those still disorder-free at age 10 are a non-random subset of 
those still disorder-free at age 20, etc. Moreover, any risk factor not a fixed marker might change 
within individuals from age 10 to 20 to 50, and the risk factor measured at different entry ages may 
have a different association with subsequent onset (age may moderate the effect of the risk factor on 
outcome). In general, the survival curves for those entering at different ages would be quite different 
from each other, and the conclusions might differ as well.  
More problematic is  the situation in  which disorder-free  individuals  over a wide span of ages,  
say 20–80 years, are sampled, and t = 0 refers to the more or less arbitrary time each individual enters 
the research study. Time of entry to an observational research study (here the focus) has no clinical 
relevance to the individuals in the population to which inferences are to be drawn. In that case, the 
observed survival curve is a mixture of the survival curves of those who enter at each age disorder-free 
with the risk factors as they are at that age, the mixture determined by the age distribution in the 
samples. Different studies are unlikely to reproduce and confirm the same findings, particularly when 
both  the  factor  (e.g.,  use  of  HRT)  and  the  disorder  itself  (e.g.,  heart  disease,  diabetes,  cancer, 
Alzheimer‘s disease) are age-related.  
Again,  there  is  one  rare  situation  that  is  an  exception  to  these  concerns:  the  constant  hazards 
situation with fixed markers. If the risk factor is constant over the lifetime of the individual and the 
probability of survival for any time span is exactly the same regardless of when a individual enters a 
study (exponential survival curve, Poisson distribution of events), it doesn‘t matter at what times the Int. J. Environ. Res. Public Health 2010, 7                 
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individuals are sampled, or whether they are sampled at the same time or what the distribution of entry 
times in the high- and low- risk subpopulations were. It doesn‘t even matter how long individuals are 
followed or why they drop out. This is also the one and only case in which the incidence rate (―events 
per person-year‖) estimates an interpretable population parameter, namely the reciprocal of the mean 
time to event, regardless of entry and exit times [11].  
However, not only are many risk factors of interest not fixed (e.g., HRT use), there are few, if any, 
real onset distributions that follow a constant hazards model. Only an inevitable outcome (e.g., death) 
can possibly follow a constant hazards model. No age-related disorder (e.g., heart disease, cancer, 
Alzheimer‘s disease or even death) can. Nevertheless epidemiological studies still occasionally use the 
incidence rate to compare the high- and low-risk subgroups [9,12] as well as other methods that depend 
on an unacknowledged assumption of constant hazards. Such studies have a high chance of drawing 
misleading conclusions [3].  
In a prospective observational study, with a representative sample from the disorder-free population 
of interest, all entered at a relevant zero time (fixed short age span or a fixed life event) and followed 
for a reasonable fixed period of time, the association between a risk factor and onset is due either to a 
causal effect of the risk factor, and/or to any factor(s) associated with that risk factor. Attribution of 
causality to risk factors detected in observational studies must be tentative. In what follows, because 
the focus is on observational studies, no causal inferences will be drawn. Inferences apply only to the 
population sampled free of the disorder at a relevant zero time. For clarity of communication, all risk 
factors considered here are binary (RF = 1 vs. RF = 0), although the principles apply more generally. 
Finally, the outcome of interest is incidence between time zero at which time RF is measured, and a 
fixed time T for all individuals, the object to compare 1-S1(T) vs. 1-S0(T).  
 
3. Statistical Significance is NOT the Goal: Public Health Significance Is 
 
Over  the  last  20  years,  considerable  attention  has  been  paid  to  the  overuse,  misuse,  abuse  of 
―statistical significance‖ [13-21]. In the way statistical hypothesis testing is usually used, to say an 
association between a risk factor and subsequent onset of disorder is statistically significant is at best to 
say that the sample was large enough to detect a non-random effect. Such a non-random effect may be 
of trivial public health significance. What is usually reported is the ―p-value‖, a statistic computed with 
the study data. A level of significance is set ‗a priori‘, ʱ (typically 0.05). If p < ʱ, then the result is said 
to be ―statistically significant‖ at the ʱ level of significance.  
However, unless the null hypothesis is absolutely true, the expected value of the p-value approaches 
zero as the sample size increases, rapidly for a strong effect, slowly for an effect of trivial public health 
significance.  Meehl  and  others  [22,23]  point  out  that  the  null  hypothesis  of  randomness  is  never 
absolutely  true.  If  so,  no  matter  how  trivial  the  non-random  association  between  risk  factor  and 
outcome, it will be found ―statistically significant‖ at whatever significance level is specified, provided 
only that the sample size is large enough. Consequently, the p-value serves more as an indicator of 
adequacy of the sample size to detect whatever effect size actually exists, than as an indicator of public 
health significance. A reviewer suggests, however, that there is a danger in ignoring the chance element 
in determining the p-value, that interpreting the p-value as equivalent to ―adequate power‖ could lead Int. J. Environ. Res. Public Health 2010, 7                 
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to unacceptable publication bias. To show public health significance, an interpretable effect size is 
necessary, a population parameter that reflects the strength of association between the risk factor and 
the onset for public health purposes. There are a number of viable such effect sizes.  
For example:  
  AUC [24-29]is the probability that a low-risk individual will have better outcome than a 
high-risk one, where ties are broken with a toss of a fair coin: here AUC = .5(S0(T) − S1(T) 
+ 1).  
  Success Rate Difference (SRD) [25,30] is the difference between the probability that a low-
risk individual will have better outcome than a high-risk one and the probability that a high-
risk individual will have a better outcome than a low-risk one: here SRD = S0(T) − S1(T) = 
2AUC − 1 (in epidemiology, SRD is usually called the risk difference).  
  Number Needed to Take (NNT) [25,31-38] equals 1/SRD or 1/(2AUC - 1). For a binary 
risk factor and incidence between 0 and T, NNT is the number of high risk individuals one 
would have to take at time 0 to find one more onset prior to T than if the same number of 
low risk individuals had been taken.  
While these are three mathematically equivalent effect sizes, generally NNT is easier to interpret in 
terms  of public health significance, and SRD and AUC are easier used in computations (e.g., for 
confidence intervals).  
There are, of course, other viable effect sizes applicable in special circumstances. For example, 
Cohen‘s d [39] is appropriate when the survival times in the high- and low- risk groups are normally 
distributed (an unusual situation): d = (μ1 − μ0)/σ, where μ1 and μ0 are the two group mean times of 
onset, and σ
2 is the average of the two group variances. Then SRD = 2ʦ(d/√2) − 1, where ʦ() is the 
cumulative standard normal distribution. In the rare situation in which the constant hazards model 
holds in both groups, SRD = (μ1 − μ2)/(μ1 + μ2) = (RR − 1)/(RR + 1), where RR, a relative risk, is the 
ratio of the incidence rates in the two groups. There is limited applicability of such specialized effect 
sizes, but, when applicable, they are easily converted to SRD (NNT, AUC).  
While  the  expected  value  of  the  p-value  approaches  zero  as  sample size increases,  the sample 
estimate of an effect size, e.g., SRD, estimates the same population parameter regardless of the sample 
size. Instead, as sample size increases, the width of its confidence interval decreases to zero, i.e., large 
sample  size  improves  the  accuracy  of  effect  size  estimation,  and  does  not  change  the  effect  
size estimated.  
A question that deserves careful future consideration is which values of NNT indicate public health 
significance, and which are trivial. For example, one would question any recommendation for costly 
and risky surgery on 500 patients to prevent one onset of coronary disease, i.e., to subject 499 patients 
unnecessarily to costly and risky surgery to prevent one onset. On the other hand, one might well be 
willing to recommend half a baby aspirin a day to 500 patients to prevent one such onset. In short, 
there is no universal answer to this question—the answer depends on how serious the disorder is, the 
consequences of untreated disorder, whether effective preventive intervention is available, how costly 
and risky such intervention might be, the vulnerability of the population and other such considerations. 
With the focus to date on ―statistically significant‖ results, such questions have yet to be discussed Int. J. Environ. Res. Public Health 2010, 7                 
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seriously. Instead larger and larger sample sizes are used to detect ever smaller effect sizes, many of 
trivial public-health significance. 
Epidemiologists often use the Odds Ratio (OR) as such an effect size, but OR is not viable in this 
role. Historically, OR was introduced as the likelihood-ratio test statistic to test the null hypothesis of 
randomness. OR remains useful as a detector of non-randomness, for example, in logistic regression 
analysis models: OR equal to 1 indicates random association; greater than 1, positive association, and 
less than 1, negative association. However, there is no magnitude of Odds Ratio unequal to 1 that 
unequivocally indicates public health significance.  
Many arguments have been put forward in recent years to support that contentious point [40-44], but 
let us here consider only one closely related to the consideration of time. In Figure 2 is shown the ROC 
(Receiver Operating Characteristic) plane in which the two survival curves shown in Figure 1 are 
compared. Here 1-S1(t) is graphed against 1-S0(t) for all values of t. These values connected with each 
other and with the two endpoints at (0,0) and (1,1) form the ROC curve comparing the RF = 1 and  
RF = 0 groups on time to onset (AUC is the area under this ROC curve). If there were only random 
association between the risk factor and onset, the ROC curve would coincide with the diagonal line 
from (0,0) to (1,1): the Random ROC. Here the ROC curve clearly indicates non-random association. 
The ROC curve crosses the Random ROC when t = T*, and as t increases, all points converge to the 
single point (0.5,0.3) determined by the proportion of the two groups who will eventually have this 
non-inevitable onset.  
Figure 2. ROC curve comparing survival in the ―high‖ and ―low‖ risk groups. 
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For  any  fixed  follow-up  time,  T,  there  is  one  point  on  the  ROC  curve  (1-S1(T),  1-S0(T))  that 
indicates the strength of association between the risk factor and that particular incidence. The SRD for 
such a binary outcome is proportional to the distance between that point and the Random ROC[42]. 
Since all ROC curves begin in the lower corner of the ROC plane, it is clear that the SRD measuring 
the association between the risk factor and any incidence depends strongly on T, and will always 
approach SRD = 0 as T approaches zero. However, Odds Ratio often tends to go in the opposite 
direction,  becoming  very  large  for  very  short  follow-up  periods,  in  some  cases  even  approaching 
infinity as T approaches zero.  
Figure 3. Equipotency curves comparing the locus of all points (p0, p1) with p1 > p0, the 
ROC plane with Odds Ratio = p1(1 − p0)/[(1 − p1)p0] and NNT = 1/(p1 − p0) = 3. (The 
Figure 3 here selected to be equal to (OR
1/2 + 1)/(OR
1/2 − 1)).  
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To demonstrate this and to understand why this is often so, it is necessary to put OR and SRD on 
comparable scales. In Figure 3 is shown the location of all pairs of probabilities (p1, p0) that would 
yield OR = 4 (OR = p1(1 − p0)/((1 − p1)p0)),and all pairs of probabilities that would yield SRD = 1/3 or 
NNT = 1/SRD = 3 (equipotency curves[43]). The same demonstration could be done for any fixed 
value of OR > 1, with SRD = (OR
1/2 − 1)/(OR
1/2 + 1) = Y (Yule‘s Index).  
What  is  in  Figure  3  seen  is  generally  true.  SRD  is  constant  (here  equal  3)  for  all  pairs  of 
probabilities a fixed distance above the Random ROC. On the other hand, OR is constant (here equal 
4) for all values on a curve symmetric around the line p1 = 1 − p0, and beginning and ending at the 
points  of the Random  ROC at (0,0) and (1,1). For fixed OR > 1, the maximal distance from the 
Random ROC coincides with the constant distance for SRD = (OR
1/2 − 1)/(OR
1/2 + 1). That distance 
then decreases  to  zero at  both  corners of the ROC  plane.  Thus it is always true that for positive 
association, SRD < (OR
1/2 − 1)/(OR
1/2 + 1). In the special case when p1 = 1 − p0, the SRD = Y =  Int. J. Environ. Res. Public Health 2010, 7                 
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(OR
1/2 − 1)/(OR
1/2 + 1). When p0 and p1 are both of moderate size (say between 0.25 and 0.75) then 
SRD is approximately equal to Y = (OR
1/2 − 1)/(OR
1/2 + 1).  
In a ROC comparing survival curves as in Figure 3, to be informed, for example, that NNT = 3 
(SRD = 1/3) is to be assured that the location of the point (1 − S1(T), 1 − S0(T)) is bounded away from 
random association. To be informed that OR = 4 allows the possibility of being as far away from 
random as is NNT = 3, but also allows the possibility of being arbitrarily close to random association, 
particularly when T is small.  
In the comparison of any two survival curves, points corresponding to very short follow-up times 
are always near the lower left corner of the ROC plane, and very near the Random ROC. These points 
will have SRD = 1/NNT near zero indicating weak association, but since all the OR > 1 equipotency 
curves converge in that corner, these points often have very large OR. Simply stated, the problem is 
that the denominator of Odds Ratio approaches zero as T approaches zero, and division by zero tends 
both to ―explode‖ the magnitude of any ratio and to make it very unstable. For this reason and all its 
many consequences, Odds Ratio should continue to be used as an indicator of non-randomness, to test 
null hypotheses of randomness, but not to be used as an effect size. 
In Figure 4 are shown SRD = 1/NNT and Y = (OR
1/2 − 1)/(OR
1/2 + 1) for all follow-up times T, for 
the two survival curves in Figures 1,2. It can there be seen that for T near zero, OR is very large  
(Y = 0.4 corresponds to OR = 5.4), but SRD is near zero (NNT approaching infinity). For t = T*, as 
appropriate, both OR = 1 and SRD = 0 indicate random association. For t > T*, when both survival 
probabilities  are  in  the  middle  range  between  0.25  and  0.75,  SRD  is  approximately  equal  to  
Y = (OR
1/2 − 1)/(OR
1/2 + 1).  
Figure 4. Comparison of Y = (OR
1/2 - 1)/(OR
1/2 + 1) with 1/NNT for various follow-up 
times for the survival curves shown in Figure 1.  
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4. How Risk Factors “Work Together” 
 
Since the common use of Odds Ratio as if it were an effect size tends to exaggerate the association 
between risk factors and disorders, moving to use of SRD, NNT or AUC instead will only diminish the 
apparent clinical importance of many risk factors. This is unwelcome news, but probably reflective of 
the truth. A few special cases such as infectious diseases or single gene disorders aside, there are 
probably very few disorders for which a single risk factor can completely explain onset. It is likely that 
for  complex  disorders  (heart  disease,  cancer,  psychiatric  disorders)  multiple  risk  factors  ―work 
together‖ in parallel or in sequence to have influence the onset of a disorder. Thus examining how risk 
factors ―work together‖ is crucial to prediction and prevention efforts.  
To date, multiple possible risk factors are often simply included as independent variables in a linear 
model, completely ignoring (1) their timing relative to each other, (2) possible correlations between 
risk factors, (3) their possible interactive effects on incidence. Moreover the linearity assumptions and 
the link function selected (e.g., log-odds) often do not well fit the population.  
The MacArthur Model is an alternative approach that takes these factors into consideration [45-49]. 
The distribution of two binary risk factors RF1 and RF2 in the population of interest  is shown in  
Table 1. In that population the probabilities that RF1 = 1 is Q, and that RF2 = 1 is P. The parameter ρ 
(the  product  moment  correlation  or  phi  coefficient  between  the  risk  factors)  is  an  indicator  of  
non-random  association  between  the  two  risk  factors  in  that  population,  with  ρ  =  0  indicating 
stochastic independence between them.  
In Table 2 are shown the incidences between time 0 and fixed T, in each of the four subgroups 
defined by the two risk factors. When using SRDs as the effect size, the conditional SRDs for RF1 for 
the two values of RF2, and the conditional SRDs for RF2 for the two values of RF1 are also shown. The 
―main effect of RF1‖ (ME1), and the ―main effect of RF2‖ (ME2) are respectively the averages of the 
corresponding conditional SRDs, and the ―interaction effect of RF1 and RF2‖ (INT) is the difference 
between those conditional SRDs (the same for both sets of conditional SRDs).  
If RF2 were ignored, the SRD relating RF1 to outcome (for each possible value of T) is equal to:  
SRD1 = ME1 + ρ(PP‘/QQ‘)
1/2ME2 + .5*INT[(2P − 1) − ρ(PP‘/QQ‘)
1/2(2Q − 1)]. 
If RF1 were ignored, the SRD relating RF2 to outcome is equal to: 
SRD2 = ME2 + ρ(QQ‘/PP‘)
1/2ME1 + .5*INT[(2Q − 1) − ρ(QQ‘/PP‘)
1/2(2P − 1)]. 
SRD1 and SRD2 are called the ―raw‖, ―overall‖, ―marginal‖, or ―univariate‖ effects of RF1 and RF2 
on the outcome, indicating the association of that risk factor on outcome in the population sampled 
when all other risk factors are ignored. While the formulas above are exact only for two binary risk 
factors predicting incidence between 0 and fixed T, the principle is true in general. The ―raw‖ effect of 
a risk factor (SRD1 or SRD2) comprises three sources: the unique effect of the risk factor itself, the 
main effects of other risk factors correlated with the risk factor of interest, and the interactions of the 
risk factor of interest with other risk factors. How much of each source is represented depends on the 
joint distributions of the risk factors in the population (here P and Q and their correlation as indicated 
in Table 1).  Int. J. Environ. Res. Public Health 2010, 7                 
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The main effect of a risk factor of interest (ME1 or ME2) does not convey the effect size in the total 
population unless the other risk factor(s) are neither correlated (ρ = 0) nor interactive (INT = 0) for the 
risk factor of interest. Nor does the main effect of a risk factor convey the strength of association in 
each subpopulation ―matched‖ on other risk factor, unless there is no interactive effect. In short, the 
research questions addressed by the raw effect size SRD1, the conditional SRDs for risk factor 1 in the 
subpopulations with RF2 = 1 and 0, and the main effect of RF1, are all usually different, not because 
one is ―right‖ and the others ―wrong‖, but because they address the association of RF1 with outcome in 
different populations. Thus ―adjusting‖ for RF2 in a linear model does not usually ―remove the effect of 
RF2‖. It changes the research question from that of focusing on the effect size of RF1 in the total 
population sampled, to that of the common effect size of RF1 in the subpopulations defined by RF2 in 
absence of an interaction, or to some weighting of those effect sizes in the presence of an interaction, 
the weighting determined by whether or not the interaction was included in the linear model and the 
joint distribution of the risk factors.   
Table 1. The joint distribution of two binary risk factors (RF1 and RF2). with marginal 
probabilities  P  =  Prob(RF2  =  1)  and  Q  =  Prob(RF1  =  1),  and  the  product  moment 
correlation coefficient (ρ) between them.  
  RF1 = 1  RF1 = 0   
RF2 = 1  PQ + ρ(PP‘QQ‘)
1/2  PQ‘ − ρ(PP‘QQ‘)
1/2  P 
RF2 = 0  P‘Q - ρ(PP‘QQ‘)
1/2  P‘Q‘ + ρ(PP‘QQ‘)
1/2  P‘ = 1 − P 
  Q  Q‘ = 1 − Q   
Table 2. The incidence of disorder by time T for each combination of RF1 and RF2, and 
the marginal SRDs.  
  RF1 = 1  RF1 = 0  Marginal SRD for RF1  
RF2 = 1  1 − S11(T)  1 − S10(T)  S10(T) − S11(T) 
RF2 = 0  1 − S01(T)  1 − S00(T)  S00(T) − S01(T) 
Marginal SRD‘s for RF2   S01(T) − S11(T)  S00(T) − S10(T)   
 
When risk factors are coded +/-1/2 in a linear model (chosen because SRD is here the effect size):  
  Main Effect of RF1: [S10(T) − S11(T) + S00(T) − S01(T)]/2 
  Main Effect of RF2: [S01(T) − S11(T) + S00(T) − S10(T)]/2 
  Interactive Effect: [S10(T) − S11(T) − S00(T) + S01(T)] 
If there is no temporal precedence for RF1 and RF2, then there are three possible roles for RF1 and 
RF2 for the incidence in question:  
RF1 and RF2 are ―independent risk factors‖ if ρ = 0, and if both matter, i.e., INT is non-zero or both 
ME1 and ME2 are non-zero. In such cases, the two risk factors play a joint role in determining the 
outcome and would continue to be of parallel interest. For many disorders, gender and ethnicity are 
independent risk factors.  
One of RF1 or RF2 ―is proxy to‖ the other if ρ is unequal to zero (RF1 and RF2 are correlated risk 
factors), and only one matters. Thus if ME1 = INT = 0, then RF1 is proxy to RF2. If ME2 = INT = 0, 
then  RF2  is  proxy  to  RF1.  In  such  cases,  the  proxy  variable  should  be  set  aside  from  further Int. J. Environ. Res. Public Health 2010, 7                 
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consideration.  For  example,  a  measure  of  family  income  is  often  proxy  to  a  well-measured  
socio-economic index for the family, because family income is usually one component of the index, 
but less reliably measured than the index as a whole.  
RF1 and RF2 are overlapping risk factors if ρ is unequal to zero, and both matter. Thus if any two of 
ME1, ME2 and INT are not equal to zero, RF1 and RF2 are overlapping. This situation often arises 
when  two  risk  factors  tap  the  same  underlying  construct  with  about  equal,  but  less  than  perfect, 
reliability/validity.  Then  it  is  preferable  to  combine  the  two  risk  factors  to  generate  a  more 
reliable/valid  measure  of  whatever  their  common  construct.  Combining  two  somewhat  unreliable 
measures  of  the  same  construct  would  disattenuate  reliability  and  thus  increase  the  effect  size. 
Moreover, to do so might focus attention more precisely on the appropriate underlying causal factor. 
For example, infant birth-weight and gestational age tend to be highly correlated and risk factors for 
many of the same subsequent outcomes. Some measure of birth maturity that included consideration of 
both, perhaps even including other indicators of physiological and neurological maturity at birth, might 
serve prediction and prevention purposes better than either separately.  
On the other hand, when there is temporal precedence, with RF1 preceding RF2 in time, there are 
four possibilities:  
RF1 moderates RF2 if ρ = 0 and INT is non-zero. Then the conditional effect sizes for RF2 differ 
depending on whether RF1 = 1 or = 0. Since a later risk factor, RF2, ―works differently‖ depending on 
what earlier RF1 is, this suggests that the population should be stratified on RF1 for further studies. For 
example, a genotype may be a susceptibility factor for a later environmental risk factor. For those with 
one genotype, RF2 may be a strong risk factor for outcome; otherwise, RF2 may be a much weaker risk 
factor, may not be a risk factor at all, or may even be a protective factor. Indeed, seeking genetic 
moderators  of  drug  on  therapeutic  response  is  the  basis  for  current  interest  in  pharmacogenetics. 
Moderators are also the basis of personalized medicine[50-53] 
RF2 mediates RF1 if ρ is non-zero, and either INT or ME2 is non-zero. In this case, RF2 explains part 
of the effect of earlier RF1 on the outcome. When a mediator is identified, this suggests the possibility 
of a chain leading from RF1 through RF2 to the outcome. For example, unsafe sex practices lead to 
HIV infection that leads to onset of AIDS: HIV infection mediates the effect of unsafe sex practices on 
AIDS.  Mediator  relationships  are  important  in  that  the  chain  provides  multiple  opportunities  for 
preventive  intervention:  one  might  break  the  chain  by  breaking  any  of  the  links  in  
the chain.  
RF2 is proxy to RF1 if ρ is non-zero, and if MS2 and INT are both zero. As is the case for proxy risk 
factors in absence of temporal precedence, the proxy factor should be set aside. Gender, for example is 
a risk factor for teen onset of depression. There are many correlates of gender during the pre-teen years, 
e.g., ball-throwing ability at age 10, that might be found to be risk factors for teen-onset depression 
when considered individually, but would be found proxy to gender when both were considered. It is 
probably  not  worthwhile  to  teach  young  girls  to  throw  a  ball  better  to  prevent  
teen depression.  
RF1 and RF2 are independent risk factors if ρ = 0, but INT = 0, i.e., RF1 does not moderate RF2. As 
is the case for independent risk factors in absence of temporal precedence, both factors would continue 
to be of parallel interest.  Int. J. Environ. Res. Public Health 2010, 7                 
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It  should  be  noted  that  these  definitions  are  more  precise  than  certain  current  usages  in 
epidemiology. For example, ―independent risk factors‖ in the MacArthur model are required to be 
stochastically independent of each other. Usual usage of the term does not require such independence. 
In the way the term is often used, only proxy risk factors would not be labeled independent risk factors, 
given large enough sample sizes.  
The Last[1] definitions of ―mediator‖ (or ―mediating variable‖ or ―intermediate variable‖) and of 
―moderator variable‖ (or ―qualifier variable‖) require that the causal pathway from the independent 
(risk factor of interest) to the dependent variable (onset) be known. Such information is generally not 
available to a cohort study. Here the issues are, first, temporal precedence and correlation and then the 
joint association of two risk factors with the outcome. Causality is neither assumed nor inferred.  
Moreover the term ―confounder‖ is avoided. Last defines the term as ―A variable that can cause or 
prevent the outcome of interest, is not an intermediate variable (mediator), and is associated with the 
factor  under  investigation.‖  (Page  35).  That  would  preclude  mediators  explicitly,  and  preclude 
moderators  and  independent  risk  factors  because  they  are  not  associated  with  the  factor  under 
investigation, leaving proxies or overlapping factors. However, in practice, the term ―confounder‖ is 
often used more loosely to refer to risk factors in which the researcher is not specifically interested. 
Thus in a study examining the relationship of diet and exercise to onset of obesity, a dietician might 
designate exercise as a ―confounder‖, while an exercise physiologist might designate diet as a ―confounder‖.  
There is as yet little history of seeking moderating/mediating relationships between risk factors for 
specific  outcomes.  Consequently,  how  to  conduct  such  a  search  to  general  moderator/mediator 
hypothesis, and how to conduct studies to formally test such hypotheses, is still work in progress. 
However, there are a few examples in the literature that might suggest possible options [54-60]. 
 
5. Discussion 
 
Many of the problems here discussed are long and well-known, and yet continue to occur. For 
example, Caspi and colleagues [57] reported in 2003 on the moderating effect of a gene (5-HTT) on an 
environmental  risk  factor  (stress)  on  major  depression  (DSM-IV  definition)  in  a  prospective 
community cohort followed from birth to 26 years. Their finding was particularly interesting since it 
suggests  a  genetic  moderator  of  an  environmental  effect  on  a  disorder.  Risch  et  al.  in  2009  [60] 
evaluated whether that finding had since been confirmed or refuted. However, of the 13 studies they 
reported as attempts to replicate, 8 were cross-sectional studies, that could legitimately evaluate neither 
stress  as  a  risk  factor  for  major  depression,  nor  any  moderator hypothesis.  Of the five  remaining 
prospective cohort studies, none covered the same age range as did the Caspi et al. study, with two 
sampling those 65 years of age or older. No effect sizes other than Odds Ratios were reported for any 
of the studies. Thus, none of the reported studies actually evaluated the same effect as did the Caspi et 
al. study, largely because issues related to time were ignored.  
Science progresses by identifying its weaknesses and repairing them. However, it is always very 
hard to give up methods long used in previous studies and thus very familiar, to be replaced with new 
and unfamiliar methods. ―That‘s not the way it is always done, or the way everyone does it!‖ is a 
common rejoinder to suggestions for alternative approaches to deal with the problems here discussed.  Int. J. Environ. Res. Public Health 2010, 7                 
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Such resistance is particularly and predictably strong when the alternative approaches are more 
difficult and costly to implement, which is here true. To be asked to stratify a mixed age sample, say 
20–80 years of age, into relatively short age strata (say entry at 20–24, 25–29, etc.), and to do analysis 
separately within each age stratum, results in a reduction of sample size and thus power to detect 
effects, inevitably an unwelcome suggestion. However, the alternative is the risk of detection of false 
positive results.  
Resistance is particularly, and again, understandably, strong when alternative methods are less likely 
to produce ―significant‖ results, and more likely to indicate that the effect of any single risk factor is 
quite weak, because such alternative methods counter the tendency of incorrect methods to produce 
false positive results. This may be one of the major reasons why Odds Ratio has been so hard to 
displace  as  an  effect  size:  it tends to  exaggerate what  are often trivial  associations  and results  in 
publications  of  results  that  only  later  are  shown  to  be  exaggerations  at  best,  and  at  worst,  false  
positive results. 
The rejoinder hardest to refute is that the effect of time can be dealt with simply by ―adjusting for 
time‖ in a linear model. In some cases this may indeed be possible. However, the assumptions and fit 
of such models should be carefully checked, for if the assumptions that underlie valid results from 
application of such models do not hold in the population sampled, the results of such adjustments may 
be more biased than the results in absence of adjustment.  
In summary, the issue of time should be central to all thinking in epidemiology research, which 
would necessitate careful thinking about sampling, measurement, design, analysis, and, perhaps most 
important,  about  the  interpretation  of  the  results  from  such  studies  that  might  influence  clinical 
decision-making and subsequent clinical research.  
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